Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Seattle Genetics, Inc. Genentech |
---|---|
Information provided by: | Seattle Genetics, Inc. |
ClinicalTrials.gov Identifier: | NCT00103779 |
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin Lymphoma |
Drug: SGN-40 (anti-huCD40 mAb) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma |
Enrollment: | 50 |
Study Start Date: | December 2004 |
Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: SGN-40 (anti-huCD40 mAb)
1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
|
A minimum of 3 patients will be entered into each dose-level cohort for 5 weeks. A dose-escalation schema will be employed in cohorts. The initial dose starts at 1 mg/kg on Day 1 and 4 followed by 2mg/kg on Day 8. Dose escalation will occur on weeks 3-5 with a maximum weekly dose of 8 mg/kg. Patients who meet criteria of at least partial response will be eligible for additional 4 weekly doses at highest dose tolerated.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have the following required baseline laboratory data:
Exclusion Criteria:
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
Stanford University | |
Stanford, California, United States, 94305 | |
United States, Florida | |
University of Miami | |
Miami, Florida, United States, 33136 | |
United States, New York | |
Cornell University | |
New York, New York, United States, 10029 | |
United States, Texas | |
University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Study Director: | Jonathan Drachman, MD | Seattle Genetics, Inc. |
Responsible Party: | Seattle Genetics, Inc. ( Jonathan Drachman, MD ) |
Study ID Numbers: | SG040-0002 |
Study First Received: | February 14, 2005 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00103779 |
Health Authority: | United States: Food and Drug Administration |
Antigens, CD40 Antibody, Monoclonal Lymphoma, Non-Hodgkin Lymphoma, B-Cell Hematologic Diseases |
Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Lymphoma |
Antibodies, Monoclonal Lymphoma, B-Cell Lymphatic Diseases Antibodies Immunoproliferative Disorders Hematologic Diseases |
B-cell lymphomas Lymphoma, small cleaved-cell, diffuse Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma Immunoglobulins |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |